IMbrave150: A randomised phase III study of atezolizumab 1 bevacizumab vs sorafenib in locally advanced or metastatic hepatocellular carcinoma

被引：0
|
作者：
Qin, S. [1 ]
Cheng, A-L. [2 ]
Ducreux, M. P. [3 ]
Galle, P. R. [4 ]
Zhu, A. [5 ]
Kim, T-Y. [6 ]
Xu, D-Z. [7 ]
Verret, W. [8 ]
Liu, J. [7 ]
Finn, R. S. [9 ]
Ikeda, M. [10 ]
机构：
[1] Peoples Liberat Army 81 Hosp, Ctr Canc, Nanjing, Jiangsu, Peoples R China
[2] Natl Taiwan Univ Hosp, Dept Oncol, Taipei, Taiwan
[3] Gustave Roussy, Gastrointestinal Unit, Villejuif, France
[4] Univ Med Mainz, Dept Internal Med, Mainz, Germany
[5] Harvard Med Sch, Massachusetts Gen Hosp, Ctr Canc, Boston, MA USA
[6] Seoul Natl Univ, Med Oncol Ctr, Coll Med, Seoul, South Korea
[7] F Hoffmann La Roche Ltd, Prod Dev Oncol, Shanghai, Peoples R China
[8] Genentech Inc, Prod Dev Oncol, San Francisco, CA 94080 USA
[9] Univ Calif Los Angeles, Jonsson Comprehens Canc Ctr, Geffen Sch Med, Los Angeles, CA 90024 USA
[10] Natl Canc Ctr Hosp East, Hepatobiliary & Pancreat Oncol, Kashiwa, Chiba, Japan
来源：
ANNALS OF ONCOLOGY | 2018年 / 29卷
关键词：
D O I：
暂无
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
210TiP
引用
收藏
页数：1
相关论文
共 50 条
  • [31] Letter regarding "Impact of Bevacizumab Being Skipped due to Adverse Events of Special Interest for Bevacizumab in Patients with Unresectable Hepatocellular Carcinoma Treated with Atezolizumab plus Bevacizumab: An Exploratory Analysis of the Phase III IMbrave150 Study"
    Hatanaka, Takeshi
    Hiraoka, Atsushi
    Tada, Toshifumi
    Kakizaki, Satoru
    LIVER CANCER, 2024, 13 (06) : 669 - 670
  • [32] Reply to the Letter Regarding "Impact of Bevacizumab Being Skipped due to Adverse Events of Special Interest for Bevacizumab in Patients with Unresectable Hepatocellular Carcinoma Treated with Atezolizumab plus Bevacizumab: An Exploratory Analysis of the Phase III IMbrave150 Study"
    Kudo, Masatoshi
    Tsuchiya, Kaoru
    Yamashita, Tatsuya
    Koga, Hironori
    Nakagawa, Yuki
    Ikeda, Masafumi
    LIVER CANCER, 2024, 13 (06) : 671 - 673
  • [33] Patient-reported outcomes (PROs) from the Phase III IMbrave150 trial of atezolizumab (atezo) plus bevacizumab (bev) vs sorafenib (sor) as first-line treatment (tx) for patients (pts) with unresectable hepatocellular carcinoma (HCC)
    Galle, Peter R.
    Finn, Richard S.
    Qin, Shukui
    Ikeda, Masafumi
    Zhu, Andrew X.
    Kim, Tae-You
    Kudo, Masatoshi
    Breder, Valeriy Vladimirovich
    Merle, Philippe
    Kaseb, Ahmed Omar
    Li, Daneng
    Mulla, Sohail
    Verret, Wendy
    Xu, Derek-Zhen
    Hernandez, Sairy
    Liu, Juan
    Huang, Chen
    Lim, Ho Yeong
    Cheng, Ann-Lii
    Ducreux, Michel
    JOURNAL OF CLINICAL ONCOLOGY, 2020, 38 (04)
  • [34] Early response and safety of atezolizumab plus bevacizumab for unresectable hepatocellular carcinoma in patients who do not meet IMbrave150 eligibility criteria
    Sho, Takuya
    Suda, Goki
    Ogawa, Koji
    Kimura, Megumi
    Kubo, Akinori
    Tokuchi, Yoshimasa
    Kitagataya, Takashi
    Maehara, Osamu
    Ohnishi, Shunsuke
    Shigesawa, Taku
    Nakamura, Akihisa
    Yamada, Ren
    Ohara, Masatsugu
    Kawagishi, Naoki
    Natsuizaka, Mitsuteru
    Nakai, Masato
    Morikawa, Kenichi
    Furuya, Ken
    Baba, Masaru
    Yamamoto, Yoshiya
    Suzuki, Kazuharu
    Izumi, Takaaki
    Meguro, Takashi
    Terashita, Katsumi
    Ito, Jun
    Miyagishima, Takuto
    Sakamoto, Naoya
    HEPATOLOGY RESEARCH, 2021, 51 (09) : 979 - 989
  • [35] Reply to correspondence on "Genomic biomarkersto predict response to atezolizumab plus bevacizumab immunotherapy in hepatocellular carcinoma: Insights from the IMbrave150 trial"
    Kanzaki, Hiroaki
    Hoshida, Yujin
    CLINICAL AND MOLECULAR HEPATOLOGY, 2025, 31 (01)
  • [36] Correspondence to editorial 2 on "Genomic biomarkers to predict response to atezolizumab plus bevacizumab immunotherapy in hepatocellular carcinoma: insights from the IMbrave150 trial"
    Yim, Sun Young
    Lee, Sung Hwan
    Kim, Ji Hoon
    Lee, Sunyoung S.
    Kaseb, Ahmed O.
    Lee, Ju-Seog
    CLINICAL AND MOLECULAR HEPATOLOGY, 2025, 31 (01)
  • [37] IMbrave150: Updated overall survival (OS) data from a global, randomized, open-label phase III study of atezolizumab (atezo) plus bevacizumab (bev) versus sorafenib (sor) in patients (pts) with unresectable hepatocellular carcinoma (HCC).
    Finn, Richard S.
    Qin Shukui
    Ikeda, Masafumi
    Galle, Peter R.
    Ducreux, Michel
    Kim, Tae-You
    Lim, Ho Yeong
    Kudo, Masatoshi
    Breder, Valeriy Vladimirovich
    Merle, Philippe
    Kaseb, Ahmed Omar
    Li Daneng
    Verret, Wendy
    Shao Hui
    Liu Juan
    Li Lindong
    Zhu, Andrew X.
    Chen, Ann-Lii
    JOURNAL OF CLINICAL ONCOLOGY, 2021, 39 (03)
  • [38] IMbrave150: updated efficacy and safety by risk status in patients (pts) receiving atezolizumab (atezo) plus bevacizumab (bev) vs sorafenib (sor) as first-line treatment for unresectable hepatocellular carcinoma (HCC)
    Finn, Richard S.
    Qin, Shukui
    Ikeda, Masafumi
    Galle, Peter R.
    Ducreux, Michel
    Mertens, Joachim
    Kim, Tae-You
    Kudo, Masatoshi
    Lim, Ho Yeong
    Breder, Valeriy
    Merle, Philippe
    Kaseb, Ahmed
    Li, Daneng
    Feng, Yin-Hsun
    Verret, Wendy
    Nicholas, Alan
    Li, Lindong
    Ma, Ning
    Zhu, Andrew X.
    Cheng, Ann-Lii
    SWISS MEDICAL WEEKLY, 2021, 151 : 25 - 26
  • [39] IMbrave150: Updated efficacy and safety by risk status in patients (pts) receiving atezolizumab (atezo) plus bevacizumab (bev) vs sorafenib (sor) as first-line treatment for unresectable hepatocellular carcinoma (HCC).
    Finn, Richard S.
    Qin, Shukui
    Ikeda, Masafumi
    Galle, Peter R.
    Ducreux, Michel
    Kim, Tae-You
    Kudo, Masatoshi
    Lim, Ho Yeong
    Breder, Valeriy
    Merle, Philippe
    Kaseb, Ahmed
    Li, Daneng
    Feng, Yin-Hsun
    Verret, Wendy
    Nicholas, Alan
    Li, Lindong
    Ma, Ning
    Zhu, Andrew X.
    Cheng, Ann-Lii
    CANCER RESEARCH, 2021, 81 (13)
  • [40] Correspondence to letter to the editor on "Genomic biomarkers to predict response to atezolizumab plus bevacizumab immunotherapy in hepatocellular carcinoma: Insights from the IMbrave150 trial"
    Lee, Sung Hwan
    Yim, Sun Young
    Kim, Ji Hoon
    Lee, Sunyoung S.
    Kaseb, Ahmed
    Wei, Peng
    Lee, Ju-Seog
    CLINICAL AND MOLECULAR HEPATOLOGY, 2025, 31 (01)
12345